When a company has numerous clinical programs like IHL it is really easy to lose track of the value that has been created with each program. In other words, is the sum of the parts greater than the whole?
It’s also really easy to become a screen junky. How many shares at 23.5c? Did that sell order just move? Maybe the chartists are right but the only double bottom I’ve seen is at the local fish and chip shop? Omg, omg, Omg.
Below are some companies with single facet programs.
Mind Med has a US$750 million market cap (A$1 billion) and was recently included in the FTSE Russell 3000 index, which measures the performance of the largest 3,000 US companies.
They only have one clinical trial at the Phase 2A level, with two others at a pre-clinical stage.
Compass Pathways has a US$1.5 billion market cap (A$2 billion) and has commenced a Phase 2b clinical trial.
GW Pharma created one CBD drug, Epidiolex and recently received a takeover offer from Jazz Pharma for US$7.2 billion (A$9.7 billion).
IHL has one Phase 2b clinical trial underway (Obstructive Sleep Apnea), one Phase 2 commencing soon (Psilocybin assisted psychotherapy for GAD) and 2 pre-clinical trials, including 675A which looks like it may be a multi use drug candidate and has completed a successful pre-IND meeting with the FDA.
IHL has a $240 million market cap (US$180 million) and will be listing in the US with the above companies as peers.
The traders will always crow about making 15%. Big egos, small profits. Good luck to them but I couldn’t care less.
DYOR. All the information is there.
Add to My Watchlist
What is My Watchlist?